Advertisement

Amino Acids

, Volume 50, Issue 9, pp 1301–1305 | Cite as

Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts

  • F. I. Tade
  • W. G. WilesIV
  • G. Lu
  • B. Bilir
  • O. Akin-Akintayo
  • J. S. Lee
  • D. Patil
  • W. Yu
  • C. Ormenisan Gherasim
  • B. Fei
  • C. S. Moreno
  • A. O. Osunkoya
  • E. J. Teoh
  • S. Oka
  • H. Okudaira
  • M. M. Goodman
  • D. M. SchusterEmail author
Short Communication
  • 121 Downloads

Abstract

We investigated if previously demonstrated inhibition of fluciclovine (18F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Partial inhibition of fluciclovine uptake by BCH and MeAIB can be demonstrated in vivo similar to previous in vitro modeling.

Keywords

Fluciclovine Prostate cancer PC3 Amino acid transport Axumin 

Notes

Acknowledgements

Research reported in this publication was supported in part by the Cancer Animal Models Shared Resource, a core supported by the Winship Cancer Institute of Emory University and Cancer Center Support Grant P30 CA138292.

Funding

This study was otherwise internally funded.

Compliance with ethical standards

Conflict of interest

Emory University licensed and approved the 18F-fluciclovine patent technology in accordance with the Emory Conflict of Interest Committee policies. M. M. Goodman and Emory University are eligible to receive royalties derived from the sale of 18F-fluciclovine. H. Okudaira and S. Oka are employees of Nihon Medi-Physics Co., Ltd. (NMP) and collaborate with M. M. Goodman and D. M. Schuster on preclinical and clinical studies involving 18F-fluciclovine. F. I. Tade, O. Akin-Akintayo, and D. M. Schuster receive funding/resources from Blue Earth Diagnostics Ltd. and Nihon Medi-Physics Co., Ltd. through the Emory University Office of Sponsored Projects for research outside that reported in this manuscript. All other co-authors declared no conflicts of interest.

Research involving human participants and/or animals

This study was performed with the approval of the Institutional Animal Care and Use Committee. All procedures performed in this study using animals were in accordance with institutional and/or national guidelines and ethical standards for the care and use of animals. No human studies were conducted.

Informed consent

No human studies were conducted.

References

  1. Kim CS, Cho SH, Chun HS et al (2008) BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31(6):1096–1100CrossRefPubMedGoogle Scholar
  2. Nye JA, Schuster DM, Yu W et al (2007) Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med Off Publ Soc Nucl Med 48(6):1017–1020.  https://doi.org/10.2967/jnumed.107.040097 CrossRefGoogle Scholar
  3. Odewole OA, Tade FI, Nieh PT et al (2016) Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging 43(10):1773–1783.  https://doi.org/10.1007/s00259-016-3383-8 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Oka S, Okudaira H, Yoshida Y et al (2012) Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol 39(1):109–119.  https://doi.org/10.1016/j.nucmedbio.2011.06.008 CrossRefPubMedGoogle Scholar
  5. Oka S, Okudaira H, Ono M et al (2014) Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with l-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 16(3):322–329.  https://doi.org/10.1007/s11307-013-0693-0 CrossRefPubMedGoogle Scholar
  6. Okudaira H, Shikano N, Nishii R et al (2011) Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med Off Publ Soc Nucl Med 52(5):822–829.  https://doi.org/10.2967/jnumed.110.086074 CrossRefGoogle Scholar
  7. Okudaira H, Nakanishi T, Oka S et al (2013) Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nucl Med Biol 40(5):670–675.  https://doi.org/10.1016/j.nucmedbio.2013.03.009 CrossRefPubMedGoogle Scholar
  8. Okudaira H, Oka S, Ono M et al (2014) Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol 16(6):756–764.  https://doi.org/10.1007/s11307-014-0756-x CrossRefPubMedPubMedCentralGoogle Scholar
  9. Ono M, Oka S, Okudaira H et al (2013) Comparative evaluation of transport mechanisms of trans-1-amino-3-[(1)(8)F]fluorocyclobutanecarboxylic acid and l-[methyl-(1)(1)C]methionine in human glioma cell lines. Brain Res 1535:24–37.  https://doi.org/10.1016/j.brainres.2013.08.037 CrossRefPubMedGoogle Scholar
  10. Ono M, Oka S, Okudaira H et al (2015) [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nucl Med Biol 42(11):887–892.  https://doi.org/10.1016/j.nucmedbio.2015.07.005 CrossRefPubMedGoogle Scholar
  11. Sakata T, Ferdous G, Tsuruta T et al (2009) l-Type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59(1):7–18.  https://doi.org/10.1111/j.1440-1827.2008.02319.x CrossRefPubMedGoogle Scholar
  12. Schuster DM, Savir-Baruch B, Nieh PT et al (2011) Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 259(3):852–861.  https://doi.org/10.1148/radiol.11102023 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Schuster DM, Nanni C, Fanti S et al (2014a) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med Off Publ Soc Nucl Med 55(12):1986–1992.  https://doi.org/10.2967/jnumed.114.143628 CrossRefGoogle Scholar
  14. Schuster DM, Nieh PT, Jani AB et al (2014b) Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 191(5):1446–1453.  https://doi.org/10.1016/j.juro.2013.10.065 CrossRefPubMedGoogle Scholar
  15. Schuster DM, Nanni C, Fanti S (2016a) Evaluation of prostate cancer with radiolabeled amino acid analogs. J Nucl Med Off Publ Soc Nucl Med 57(Suppl 3):61S–66S.  https://doi.org/10.2967/jnumed.115.170209 CrossRefGoogle Scholar
  16. Schuster DM, Nanni C, Fanti S (2016b) PET tracers beyond FDG in prostate cancer. Semin Nucl Med 46(6):507–521.  https://doi.org/10.1053/j.semnuclmed.2016.07.005 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • F. I. Tade
    • 1
  • W. G. WilesIV
    • 2
  • G. Lu
    • 3
  • B. Bilir
    • 4
  • O. Akin-Akintayo
    • 1
  • J. S. Lee
    • 1
  • D. Patil
    • 2
  • W. Yu
    • 1
  • C. Ormenisan Gherasim
    • 4
  • B. Fei
    • 1
  • C. S. Moreno
    • 4
  • A. O. Osunkoya
    • 2
    • 4
    • 5
  • E. J. Teoh
    • 6
  • S. Oka
    • 7
  • H. Okudaira
    • 7
  • M. M. Goodman
    • 1
  • D. M. Schuster
    • 1
    Email author
  1. 1.Department of Radiology and Imaging SciencesEmory UniversityAtlantaUSA
  2. 2.Winship Cancer InstituteAtlantaUSA
  3. 3.Department of OtolaryngologyStanford UniversityStanfordUSA
  4. 4.Department of Pathology and Laboratory MedicineEmory UniversityAtlantaUSA
  5. 5.Department of UrologyEmory UniversityAtlantaUSA
  6. 6.Department of OncologyCancer Imaging Centre Oxford, University of OxfordOxfordUK
  7. 7.Research CenterNihon Medi-Physics Co., Ltd.ChibaJapan

Personalised recommendations